Hemangiomas is an indication for drug development with over 10 pipeline drugs currently active. According to GlobalData, preregistered drugs for Hemangiomas have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Hemangiomas compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Likelihood of Approval Analysis for Hemangiomas

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Hemangiomas overview

Hemangiomas are the most common benign tumors in infants also known as strawberry marks. It is a non-cancerous vascular tumors caused by endothelial cell proliferation. Strawberry like birth marks appears on the skin within one to three weeks after the birth in around 4-5% of newborns. Most of the hemangiomas subsides without treatment and mostly occurs in premature infants. Superficial hemangioma, deep hemangioma, and combination of both are the three types of hemangiomas. Physical examination of the skin, biopsy tests and laboratory examination to evaluate the levels of GLUT 1 and imaging studies MRI, CT scan are done. As the condition gets subsided on its own no treatment is necessary but in complicated cases beta blockers, oral prednisone with drug adjustment and oral and topical corticosteroids.

For a complete picture of PTSR and LoA scores for drugs in Hemangiomas, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.